{"DataElement":{"publicId":"2986871","version":"1","preferredName":"Disease or Disorder Malignant Testicular Germ Cell Tumor Status Type","preferredDefinition":"A description of the malignant testicular germ cell tumor disease status.","longName":"2512861v1.0:2986856v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2512861","version":"1","preferredName":"Disease or Disorder Status","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A condition or state at a particular time.","longName":"2404658v1.0:2320064v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2320064","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC71B93E-037B-5AD9-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B898979-184A-3A90-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2986856","version":"1","preferredName":"Malignant Testicular Germ Cell Tumor Status Type","preferredDefinition":"A malignant tumor predominantly affecting young men and often associated with cryptorchidism.  Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor. -- 2004_A condition or state at a particular time._Type; a subdivision of a particular kind of thing.","longName":"2986856v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"80","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No evidence of disease as defined clincally, tumor markers within normal limits","valueDescription":"No evidence of disease as defined clincally, tumor markers within normal limits","ValueMeaning":{"publicId":"3320356","version":"1","preferredName":"No evidence of disease as defined clincally, tumor markers within normal limits","longName":"3320356","preferredDefinition":"No evidence of disease as defined clincally, tumor markers within normal limits","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3234AC1-8525-E995-E040-BB89AD431D7E","latestVersionIndicator":"Yes","beginDate":"2011-12-02","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-12-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3234AC1-853E-E995-E040-BB89AD431D7E","beginDate":"2010-01-14","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-12-02","modifiedBy":"ONEDATA","dateModified":"2011-12-02","deletedIndicator":"No"},{"value":"No evidence of disease as defined surgically, tumor markers within normal limits","valueDescription":"No evidence of disease as defined surgically, tumor markers within normal limits","ValueMeaning":{"publicId":"3320357","version":"1","preferredName":"No evidence of disease as defined surgically, tumor markers within normal limits","longName":"3320357","preferredDefinition":"No evidence of disease as defined surgically, tumor markers within normal limits","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3234AC1-8576-E995-E040-BB89AD431D7E","latestVersionIndicator":"Yes","beginDate":"2011-12-02","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-12-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3234AC1-858F-E995-E040-BB89AD431D7E","beginDate":"2010-01-14","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-12-02","modifiedBy":"ONEDATA","dateModified":"2011-12-02","deletedIndicator":"No"},{"value":"Not evaluable","valueDescription":"unevaluable","ValueMeaning":{"publicId":"2568256","version":"1","preferredName":"unevaluable","longName":"2568256","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D7AD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-29","modifiedBy":"CURTIST","dateModified":"2006-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B177CA04-2079-81A2-E040-BB89AD437C67","beginDate":"2010-01-14","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-11-11","modifiedBy":"ONEDATA","dateModified":"2011-11-11","deletedIndicator":"No"},{"value":"Residual tumor mass, elevated tumor markers","valueDescription":"Residual Neoplasm Elevated Tumor Marker","ValueMeaning":{"publicId":"2986861","version":"1","preferredName":"Residual Neoplasm Elevated Tumor Marker","longName":"2986861","preferredDefinition":"Remaining or left behind.: (NEE-o-PLAY-zha) Abnormal and uncontrolled cell growth.: Elevated; raised or increased.: A substance sometimes found in an increased amount in the blood, other body fluids, or tissues and which may mean that a certain type of cancer is in the body. Examples of tumor markers include CA 125 (ovarian cancer), CA 15-3 (breast cancer), CEA (ovarian, lung, breast, pancreas, and gastrointestinal tract cancers), and PSA (prostate cancer). Also called biomarker.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Residual","conceptCode":"C37895","definition":"Remaining or left behind.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Elevated","conceptCode":"C25493","definition":"Raised or increased above normal levels or limits.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tumor Marker","conceptCode":"C17220","definition":"A substance present in or produced by a tumor or by the host, that can be used for differentiating neoplastic from normal tissue based on measurements in body fluids, secretions, cells, and/or tissues. Markers are used in diagnosis, staging and prognosis of cancer, provide an estimation of tumor burden, and serve for monitoring effects of therapy, detecting recurrence, localization of tumors, and screening in general populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D24EE83-BA89-C27D-E040-BB89AD4317B4","latestVersionIndicator":"Yes","beginDate":"2010-01-14","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-01-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B177CA04-208D-81A2-E040-BB89AD437C67","beginDate":"2010-01-14","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-11-11","modifiedBy":"ONEDATA","dateModified":"2011-11-11","deletedIndicator":"No"},{"value":"Tumor marker elevation only","valueDescription":"Single Elevation Tumor Marker","ValueMeaning":{"publicId":"2986857","version":"1","preferredName":"Single Elevation Tumor Marker","longName":"2986857","preferredDefinition":"Not accompanied by another or others.: Elevation; the condition of being elevated.: A substance sometimes found in an increased amount in the blood, other body fluids, or tissues and which may mean that a certain type of cancer is in the body. Examples of tumor markers include CA 125 (ovarian cancer), CA 15-3 (breast cancer), CEA (ovarian, lung, breast, pancreas, and gastrointestinal tract cancers), and PSA (prostate cancer). Also called biomarker.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Single","conceptCode":"C48440","definition":"Not accompanied by another or others; exclusive of anyone or anything else.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Elevation","conceptCode":"C25494","definition":"The condition of being elevated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tumor Marker","conceptCode":"C17220","definition":"A substance present in or produced by a tumor or by the host, that can be used for differentiating neoplastic from normal tissue based on measurements in body fluids, secretions, cells, and/or tissues. Markers are used in diagnosis, staging and prognosis of cancer, provide an estimation of tumor burden, and serve for monitoring effects of therapy, detecting recurrence, localization of tumors, and screening in general populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D24EE83-B9E4-C27D-E040-BB89AD4317B4","latestVersionIndicator":"Yes","beginDate":"2010-01-14","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-01-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B177CA04-20B5-81A2-E040-BB89AD437C67","beginDate":"2010-01-14","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-11-11","modifiedBy":"ONEDATA","dateModified":"2011-11-11","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2575365","version":"1","preferredName":"Unknown","longName":"2575365","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F372-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B177CA04-20BF-81A2-E040-BB89AD437C67","beginDate":"2010-01-14","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-11-11","modifiedBy":"ONEDATA","dateModified":"2011-11-11","deletedIndicator":"No"},{"value":"Residual tumor mass, tumor markers within normal limits","valueDescription":"Residual Neoplasm Normal Tumor Marker","ValueMeaning":{"publicId":"3308159","version":"1","preferredName":"Residual Neoplasm Normal Tumor Marker","longName":"3308159","preferredDefinition":"Remaining or left behind.: A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.: Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm. (NCI): A substance sometimes found in an increased amount in the blood, other body fluids, or tissues and which may mean that a certain type of cancer is in the body. Examples of tumor markers include CA 125 (ovarian cancer), CA 15-3 (breast cancer), CEA (ovarian, lung, breast, pancreas, and gastrointestinal tract cancers), and PSA (prostate cancer). Also called biomarker.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Residual","conceptCode":"C37895","definition":"Remaining or left behind.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Normal","conceptCode":"C14165","definition":"Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tumor Marker","conceptCode":"C17220","definition":"A substance present in or produced by a tumor or by the host, that can be used for differentiating neoplastic from normal tissue based on measurements in body fluids, secretions, cells, and/or tissues. Markers are used in diagnosis, staging and prognosis of cancer, provide an estimation of tumor burden, and serve for monitoring effects of therapy, detecting recurrence, localization of tumors, and screening in general populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2045A13-83B7-ADB5-E040-BB89AD4374D9","latestVersionIndicator":"Yes","beginDate":"2011-11-18","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B2045A13-83D0-ADB5-E040-BB89AD4374D9","beginDate":"2010-01-14","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-11-18","modifiedBy":"ONEDATA","dateModified":"2011-11-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2986855","version":"1","preferredName":"Malignant Testicular Germ Cell Tumor Status Type","preferredDefinition":"A malignant tumor predominantly affecting young men and often associated with cryptorchidism.  Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor. -- 2004:A condition or state at a particular time.:Type; a subdivision of a particular kind of thing.","longName":"C9063:C25688:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Testicular Germ Cell Tumor","conceptCode":"C9063","definition":"A malignant germ cell tumor that arises from the testis. It predominantly affects young men. Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D24EE83-B9AF-C27D-E040-BB89AD4317B4","latestVersionIndicator":"Yes","beginDate":"2010-01-14","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-01-14","modifiedBy":"ONEDATA","dateModified":"2010-01-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D24EE83-B9C0-C27D-E040-BB89AD4317B4","latestVersionIndicator":"Yes","beginDate":"2010-01-14","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-01-14","modifiedBy":"KUMMEROA","dateModified":"2012-03-26","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964899","version":"1","longName":"2022r1: Testicular / Germ Cell Cancer Pre-HSCT Data","context":"NHLBI"},{"publicId":"3279271","version":"1","longName":"Disease Status","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"tc_base_curr_dx_sts_kn","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedDiagnosis:diseaseStatusCode ","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the disease status?","type":"Preferred Question Text","description":"What was the disease status?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2986871","type":"BRIDG Mapping Path","description":"PerformedDiagnosis.diseaseStatusCode WHERE PerformedDiagnosis.value = \"Malignant Testicular Germ Cell Tumor\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D24EE83-BAB3-C27D-E040-BB89AD4317B4","latestVersionIndicator":"Yes","beginDate":"2010-01-14","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-01-14","modifiedBy":"KUMMEROA","dateModified":"2021-08-10","changeDescription":". 2021-8-10 ak System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}